Literature DB >> 8220918

The positive inotropic effect of compound II, a novel analogue of sotalol, on guinea-pig papillary muscles and single ventricular myocytes.

E White1, S P Connors, E W Gill, D A Terrar.   

Abstract

1. Compound II is a novel analogue of sotalol which has been reported to be free of beta-adrenoceptor and L-type calcium channel blocking actions. The effects of compound II on the contraction of guinea-pig papillary muscles (at 2 microM) and single ventricular myocytes (at 100 nM) were investigated. 2. Exposure to compound II caused a significant increase in the contraction of both preparations. 3. Compound II prolonged the action potential of the single myocytes and increased the magnitude of the Ca-activated current which was used as a qualitative indicator of the intracellular calcium transient. 4. The ratio of first/steady state Ca-activated currents evoked by short action potentials was not modified. This may indicate that compound II does not influence the normal functioning of the sarcoplasmic reticulum stores. 5. The observations are consistent with the hypothesis that action potential prolongation by compound II reduces Ca2+ extrusion via the Na-Ca exchange. This in turn allows increased uptake of calcium into the sarcoplasmic reticulum stores so that more calcium is available for release by subsequent action potentials, leading to an increase in intracellular calcium transients and contractions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220918      PMCID: PMC2176007          DOI: 10.1111/j.1476-5381.1993.tb13776.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Actions and mechanisms of action of novel analogues of sotalol on guinea-pig and rabbit ventricular cells.

Authors:  S P Connors; E W Gill; D A Terrar
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

2.  The synthesis and potassium channel blocking activity of some (4-methanesulfonamidophenoxy)propanolamines as potential class III antiarrhythmic agents.

Authors:  S P Connors; P D Dennis; E W Gill; D A Terrar
Journal:  J Med Chem       Date:  1991-05       Impact factor: 7.446

3.  The slowing of Ca2+ signals by Ca2+ indicators in cardiac muscle.

Authors:  D Noble; T Powell
Journal:  Proc Biol Sci       Date:  1991-11-22       Impact factor: 5.349

4.  Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters.

Authors:  E Wettwer; G Scholtysik; A Schaad; H Himmel; U Ravens
Journal:  J Cardiovasc Pharmacol       Date:  1991-03       Impact factor: 3.105

5.  Action potential duration and the inotropic response to reduced extracellular potassium in guinea-pig ventricular myocytes.

Authors:  E White; D A Terrar
Journal:  Exp Physiol       Date:  1991-09       Impact factor: 2.969

6.  Changes in cytosolic calcium monitored by inward currents during action potentials in guinea-pig ventricular cells.

Authors:  D A Terrar; E White
Journal:  Proc R Soc Lond B Biol Sci       Date:  1989-11-22

7.  The effects of ryanodine and caffeine on Ca-activated current in guinea-pig ventricular myocytes.

Authors:  E White; D A Terrar
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

8.  The effects of ryanodine, EGTA and low-sodium on action potentials in rat and guinea-pig ventricular myocytes: evidence for two inward currents during the plateau.

Authors:  M R Mitchell; T Powell; D A Terrar; V W Twist
Journal:  Br J Pharmacol       Date:  1984-03       Impact factor: 8.739

9.  Sodium-calcium exchange during the action potential in guinea-pig ventricular cells.

Authors:  T M Egan; D Noble; S J Noble; T Powell; A J Spindler; V W Twist
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

10.  New calcium indicators and buffers with high selectivity against magnesium and protons: design, synthesis, and properties of prototype structures.

Authors:  R Y Tsien
Journal:  Biochemistry       Date:  1980-05-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.